S-1/A: Processa Pharmaceuticals Files Amendment for Public Offering of Common Stock and Warrants

Processa Pharmaceuticals has filed an amendment to its registration statement for a public offering of up to 9,400,705 shares of common stock, pre-funded warrants, and common warrants.

Summary

• Processa Pharmaceuticals is conducting a public offering of up to 9,400,705 shares of common stock and accompanying common warrants.
• The offering also includes pre-funded warrants for investors who would exceed a 4.99% (or 9.99%) ownership threshold.
• Each pre-funded warrant is exercisable for one share of common stock at $0.0001 per share.
• The common warrants have an exercise price equal to 100% of the combined public offering price per share and accompanying common warrant.
• The offering is on a best-efforts basis with no minimum amount required to close.
• The offering is expected to terminate on March 11, 2025.
• The company intends to use the net proceeds from the offering to continue the Phase 2 clinical trial of NGC-Cap and for working capital and other general corporate purposes.
• The company estimates net proceeds of approximately $7.3 million, assuming only shares of common stock are sold and no pre-funded warrants are sold.
• The company believes that the net proceeds from this offering, together with cash on hand, will satisfy capital needs into the third quarter of 2025.

Sentiment

Score: 4

Explanation: The document is a necessary step for the company to raise capital, but it also highlights the company's financial challenges and the risks associated with the offering. The best-efforts nature of the offering and the lack of a minimum amount required to close are concerning.

Positives

• The offering provides a pathway for Processa to fund its ongoing Phase 2 clinical trial of NGC-Cap.
• The inclusion of pre-funded warrants allows for flexibility in accommodating different investor needs.
• The company has a clear plan for the use of proceeds, focusing on clinical development and working capital.
• The company believes that the net proceeds from this offering, together with cash on hand, will satisfy capital needs into the third quarter of 2025.

Negatives

• The offering is on a best-efforts basis, meaning there is no guarantee of raising the full amount.
• The company may sell fewer securities than offered, which could significantly reduce the proceeds received.
• There is no minimum offering amount required as a condition to closing, which could result in the company being unable to fulfill all of its objectives.
• The company will need to raise additional capital in 2025 to fund operations and continue development of NGC drugs.

Risks

• The offering is on a best-efforts basis, and the company may not raise the desired amount of capital.
• There is no minimum offering amount required to close, which could result in the company being unable to fulfill all of its objectives.
• The company may need to raise additional capital in 2025 to fund operations and continue development of NGC drugs.
• The company has a history of operating losses and may never achieve profitability.
• The company's financial situation creates doubt about its ability to continue as a going concern.
• The company is subject to litigation, which could expose it to significant liabilities.
• The per share price of the company's common stock may be volatile.
• There is no established public trading market for the pre-funded warrants or common warrants.
• The common warrants are speculative in nature and may expire valueless.
• The company may issue additional equity or convertible debt securities in the future, which may result in dilution to investors.

Future Outlook

The company believes that the net proceeds from this offering, together with cash on hand, will satisfy capital needs into the third quarter of 2025. The company will need to raise additional capital in 2025 to fund operations and continue development of NGC drugs.

Industry Context

This offering is part of the broader trend of biotech companies seeking capital to fund clinical trials and drug development. The inclusion of pre-funded warrants is a common strategy to accommodate investors with ownership limitations.

Comparison to Industry Standards

• The use of a best-efforts underwriting is common for smaller biotech companies, as it reduces the risk for the underwriter but also provides less certainty for the company.
• The offering structure, including common stock, common warrants, and pre-funded warrants, is a typical approach for raising capital in the biotech sector.
• The company's focus on next-generation chemotherapy aligns with the industry's push for more effective and safer cancer treatments.
• The company's focus on improving existing drugs rather than developing novel compounds is a strategy that can reduce development risk and time.

Legal Proceedings

• On December 22, 2024, two of the investors in our February 2021 private offering filed a lawsuit alleging fraud and negligent misrepresentation in connection therewith and seeking monetary damages.
• On May 10, 2024, we filed a lawsuit against Elion Oncology, Inc. disputing the purported termination of a license agreement, which lawsuit is subject to counterclaims by Elion.

Stakeholder Impact

• Shareholders face potential dilution from the issuance of new shares and warrants.
• Employees may be affected by the company's financial situation and the need for additional capital.
• Customers may benefit from the development of new cancer treatments.
• Creditors may be concerned about the company's ability to repay debts.
• Suppliers may be affected by the company's financial situation.

Next Steps

• The company will continue the Phase 2 clinical trial of NGC-Cap.
• The company will seek to list the shares and warrants on the Nasdaq Capital Market.
• The company will need to raise additional capital in 2025 to fund operations and continue development of NGC drugs.

Key Dates

Keywords

public offering, common stock, pre-funded warrants, common warrants, clinical trial, NGC-Cap, biopharmaceutical, capital raise, best efforts, securities